Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
BIOSPECIFICS TEC RG (NQ: BSTC)
47.46 USD  -1.01 (-2.08%)
Official Closing Price  /  Updated: 8:10 PM EDT, Oct 20, 2017  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 17,376
Open 48.88
Bid (Size) 46.46 (100)
Ask (Size) 57.32 (100)
Prev. Close 48.47
Today's Range 47.33 - 48.99
52wk Range 41.00 - 58.79
Shares Outstanding 7,164,233
Dividend Yield N/A
Performance
YTD
-15.81%
-15.81%
1 Month
+2.71%
+2.71%
3 Month
-7.58%
-7.58%
6 Month
-11.90%
-11.90%
1 Year
+5.05%
+5.05%
Top News
More News
BioSpecifics Technologies Corp. to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... Read More
from PR Newswire
BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... Read More
from PR Newswire
More News
Read More
BioSpecifics Technologies Corp. Reports Second Quarter 2017 Financial Results
from PR Newswire
BioSpecifics Technologies Corp. to Present at the Jefferies 2017 Healthcare Conference
from PR Newswire
Can This Biotech Stock With 645% EPS Growth Launch New Breakout?
category IBD Data Stories
from Investor's Business Daily
Pharma Stock With Triple-Digit Growth Forming Blotchy Base
category IBD Data Stories
from Investor's Business Daily
Biotech Breakout Ahead? Incyte Rising On Success With Merk, Bristol-Myers
category IBD Data Stories
from Investor's Business Daily
BioSpecifics Technologies Corp. Reports First Quarter 2017 Financial Results
from PR Newswire
Recovering Biotech Stock Enters Buy Zone; Earns Rating Upgrade
category IBD Data Stories
from Investor's Business Daily
How Ionis Helped Rival Alnylam — But Tanked Itself — On A Key Trial
category Technology
from Investor's Business Daily
BioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine Fibroids
from PR Newswire
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial